The Future of Parkinson’s Treatment: Can HIFU Become the Gold Standard?

“Diagnosed with Parkinson’s disease over a decade ago, Robert’s once-steady grip had deteriorated, making everyday tasks like holding a cup of coffee or signing his name nearly impossible. But today marked a turning point.”

Ultrasound Today is your pulse on the future of ultrasound imaging.

Hear from active practitioners like you in our ongoing guest article series Voices from the Field and on our podcast The Scoop on Ultrasound available on Spotify, Apple Podcasts and other major podcasting platforms.

Subscribe today and receive new articles right in your email inbox.

On a warm afternoon, Robert sat in a treatment room, his hands trembling as he fidgeted nervously. Diagnosed with Parkinson’s disease over a decade ago, his once-steady grip had deteriorated, making everyday tasks like holding a cup of coffee or signing his name nearly impossible. But today marked a turning point. He was about to undergo MRI-guided high-intensity focused ultrasound (HIFU) therapy—a non-invasive treatment that held the promise of restoring the control he had long lost.

A Revolutionary Approach

For decades, Parkinson’s treatment options have been limited to drug therapy and invasive surgical procedures like deep brain stimulation (DBS). While these interventions help manage symptoms, they often come with significant side effects and ongoing maintenance.

HIFU is transforming the way Parkinson’s disease is treated. Pioneered by organizations like the Focused Ultrasound Foundation, this innovative technology requires no incisions, electrodes, or implants. Instead, it uses targeted ultrasound beams to generate heat, precisely disrupting malfunctioning brain tissue and reducing tremors and other motor symptoms.

How HIFU Works

HIFU operates on a straightforward principle: ultrasound beams are focused on a specific area of the brain, generating heat that ablates targeted tissue. This precise approach allows clinicians to address various Parkinsonian symptoms by disrupting abnormal neural activity. Targeting the thalamus through a procedure known as thalamotomy can significantly reduce tremors. Similarly, focusing on the globus pallidus or subthalamic nucleus helps alleviate dyskinesia and involuntary movements. Motor fluctuations, another hallmark of Parkinson’s, can also be managed by treating the pallidothalamic tract, a key neural circuit involved in movement control.

Currently, the FDA has approved HIFU for unilateral treatments, meaning it is performed on only one side of the brain. However, research is underway to determine whether bilateral procedures—targeting both hemispheres—can provide even greater symptom relief while maintaining safety and effectiveness.

A Safer Alternative to Surgery

Unlike deep brain stimulation (DBS), which requires the implantation of electrodes and regular device maintenance, HIFU is a non-invasive treatment with fewer risks. Patients do not undergo incisions or require implants, reducing the chances of infections, blood clots, or complications associated with hardware. MRI guidance ensures precise targeting, minimizing potential damage to surrounding brain tissue. Additionally, HIFU is typically a one-time procedure, eliminating the need for ongoing device adjustments or battery replacements, which are necessary for DBS patients.

For individuals seeking an alternative to conventional surgical approaches, HIFU presents a safer, less invasive option with fewer long-term commitments.

Beyond Symptom Management: Addressing the Root Cause

While HIFU is primarily used to relieve motor symptoms, researchers are exploring its potential to go beyond symptom management and impact the underlying progression of Parkinson’s disease. One of the most promising applications is its ability to temporarily open the blood-brain barrier (BBB). This natural protective layer prevents many drugs and therapies from reaching the brain, but with HIFU, targeted openings could allow neuroprotective treatments to reach affected areas more effectively.

Scientists are investigating various possibilities, including gene therapies designed to correct genetic deficiencies, neurorestorative drugs that may help regenerate damaged neurons, and antibodies that target the toxic buildup of alpha-synuclein, a protein linked to Parkinson’s disease.

In 2018, the Focused Ultrasound Foundation brought together experts to develop strategies for using BBB-opening techniques in Parkinson’s treatment. If successful, this approach could shift HIFU from a tool that simply manages symptoms to one that modifies or even slows the disease’s progression.

A Real-World Impact

The promise of HIFU is not just theoretical. At AdventHealth Celebration, clinicians recently treated their 500th patient with this cutting-edge therapy for essential tremors. For many of these patients, HIFU has been life-changing, restoring their ability to perform everyday tasks like writing, eating, and dressing without the debilitating effects of tremors.

While HIFU is still in its early stages as a Parkinson’s treatment, its potential is undeniable. Clinical trials continue to refine its applications, from improved targeting to disease-modifying therapies. If ongoing research proves successful, HIFU could redefine Parkinson’s care, offering a non-invasive, highly precise, and potentially curative option for millions.

The future of Parkinson’s treatment is on the horizon—and HIFU may well be at its forefront.